BioCryst Pharmaceuticals (BCRX): Profitability Outlook for 2025 Triggers Breakout to a 52-Week High!
Reading Time: 2 minutes
BioCryst Pharmaceuticals Inc. (BCRX) (i.) specializes in rare diseases. The company's main product is ORLADEYO (Berotralstat), an oral medication taken once daily for the prophylaxis of hereditary angioedema (HAE), which is approved in over 30 countries. Another product is RAPIVAB (Peramivir), an antiviral medication for the treatment of influenza. Clinical trials for BCX17725 for the treatment of Netherton syndrome and for Avoralstat for the treatment of diabetic macular edema are planned for 2025. Additionally, the company is preparing to submit...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
